These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25433941)

  • 1. [Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
    Schmutz JL
    Ann Dermatol Venereol; 2014 Dec; 141(12):815-6. PubMed ID: 25433941
    [No Abstract]   [Full Text] [Related]  

  • 2. Scrotal cutaneous side effects of sunitinib.
    Billemont B; Barete S; Rixe O
    N Engl J Med; 2008 Aug; 359(9):975-6; discussion 976. PubMed ID: 18753659
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent scrotal hemangiomas during treatment with sunitinib.
    Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
    J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
    [No Abstract]   [Full Text] [Related]  

  • 4. Sunitinib adverse event: oral bullous and lichenoid mucositis.
    Mignogna MD; Fortuna G; Leuci S; Pollio A; Ruoppo E
    Ann Pharmacother; 2009 Mar; 43(3):546-7. PubMed ID: 19240256
    [No Abstract]   [Full Text] [Related]  

  • 5. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 6. Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
    Iacovelli R; Mancini ML; Risi E; Palazzo A; Cortesi E
    Int J Dermatol; 2012 Feb; 51(2):221-2. PubMed ID: 22250635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib-induced scrotal cutaneous side-effect.
    Chou CY; Wang KH; Lin YH; Lin YT; Tsai HH
    J Dermatol; 2013 Jan; 40(1):67-8. PubMed ID: 23078345
    [No Abstract]   [Full Text] [Related]  

  • 8. Scrotal cutaneous toxicity: an uncommon but important side-effect of sunitinib.
    Gupta V; Rao A; Gupta S
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):132-3. PubMed ID: 25060046
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 10. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
    Demirci U; Coskun U; Erdem O; Ozturk B; Bilge Yilmaz I; Benekli M; Buyukberber S
    J Oncol Pharm Pract; 2011 Sep; 17(3):285-7. PubMed ID: 20551113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoporphyria.
    Kulick SM
    Dermatol Nurs; 2003 Jun; 15(3):272. PubMed ID: 12875014
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Defuentes G; Bladé JS; Berets O
    N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
    [No Abstract]   [Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 14. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ; Reid TR
    J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract]   [Full Text] [Related]  

  • 16. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
    J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
    [No Abstract]   [Full Text] [Related]  

  • 17. Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.
    Bos WE; Nijsten TE; de Jonge MJ; Hamberg AP
    Arch Dermatol; 2012 Apr; 148(4):546-7. PubMed ID: 22508887
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
    Loong HH; Yeo W
    Hong Kong Med J; 2008 Dec; 14(6):495-8. PubMed ID: 19060352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors and acute pancreatitis.
    Pezzilli R; Corinaldesi R; Morselli-Labate AM
    JOP; 2010 May; 11(3):291-3. PubMed ID: 20442535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.